19 C
New York
Thursday, June 8, 2023

BioXcel Therapeutics Inc. (NASDAQ: BTAI) May Be Attracting Institutional Investments

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for BioXcel Therapeutics Inc. (BTAI) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.04, or -0.18%, to $22.65. The BioXcel Therapeutics Inc. has recorded 12,305 volume in the after hours trading session. Recently, Yahoo Finance discussed the stock, revealing that BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference.

<25-cent Stock Takes $11T Commodities Sector Digital

One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.

All the details are in the FREE online report you can get here.


Stocks Info

BioXcel Therapeutics Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $22.69 and fluctuated between $22.94 as its day high and $20.97 as its day low. The current market capitalization of BioXcel Therapeutics Inc. is $658.01M. A total of 0.51 million shares were traded on the day, compared to an average of 511.08K shares.

Insider Activity

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, BTAI has seen 5 BUY and 5 SELL insider trades, representing the acquisition of 68,336 and the disposition of 64,864 shares. Over the last 12 months, there were 11 BUYs and 16 SELLs from insiders. Insiders purchased 509,146 shares during that period but sold 846,772.

In the most recent transaction, Nandabalan Krishnan sold 60,000 shares of BTAI for 17.32 per share on Apr 06. After the transaction, the Director now owns 0 company shares. In a previous transaction on Mar 21, Mehta Vimal sold 30,000 shares at 19.71 per share. BTAI shares that CEO and President owns now total 15,894.

Among the insiders who sold shares, Mehta Vimal disposed of 34,500 shares on Mar 20 at a per-share price of $18.32. This resulted in the CEO and President holding 15,894 shares of BTAI after the transaction. In another insider transaction, Steinhart Richard I sold 2,084 shares at $19.50 per share on Mar 15. Company shares held by the Chief Financial Officer now total 1,500.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for BTAI in the last 3 months, the mean price target is $51.80 with high estimates of $75.00 and low estimates of $22.00. In terms of 52-week highs and lows, BTAI has a high of $34.12 and a low of $8.80.

As of this writing, BTAI has an earnings estimate of -$1.62 per share for the current quarter. EPS was calculated based on a consensus of 11 estimates, with a high estimate of -$1.12 per share and a lower estimate of -$1.97. The company reported an EPS of -$1.49 in the last quarter, which was -10.40% lower than expectations of -$1.35.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. BTAI’s latest balance sheet shows that the firm has $232.97M in Cash & Short Term Investments as of fiscal 2021. There were $1.40M in debt and $16.67M in liabilities at the time. Its Book Value Per Share was $2.74, while its Total Shareholder’s Equity was $221.67M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BTAI is Buy with a score of 4.50.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles